Clinical trial Voyager
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Cancers | |
---|---|
Organ | Gastrointestinal stromal tumors (GIST) |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Blueprint Medicines Corporation |
EudraCT Identifier | 2017-003497-14 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03465722 |
Inclusion criteria | "3rd line metastatic " |
Last update |